E. Baltruškevičienė, U. Mickys, T. Žvirblis, R. Stulpinas, T. Pipirienė Želvienė, and E. Aleknavičius, “Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience”, AML, vol. 23, no. 1, pp. 24–34, Apr. 2016, doi: 10.6001/actamedica.v23i1.3267.